Scarica l'app Stockscreener
4.39
0.00%
0.00
Dopo l'orario di chiusura:
4.38
-0.010
-0.23%
Precedente Chiudi:
$4.39
Aprire:
$4.36
Volume 24 ore:
54,258
Relative Volume:
0.84
Capitalizzazione di mercato:
$83.78M
Reddito:
-
Utile/perdita netta:
$-34.17M
Rapporto P/E:
-1.9395
EPS:
-2.2635
Flusso di cassa netto:
$-47.63M
1 W Prestazione:
+1.62%
1M Prestazione:
+1.15%
6M Prestazione:
+26.88%
1 anno Prestazione:
+61.99%
Intervallo 1D:
$4.33
$4.42
Intervallo di 1 settimana:
$4.20
$4.47
Portata 52W:
$2.30
$5.12
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.39 | 83.78M | 0 | -34.17M | -47.63M | -2.2635 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Iniziato | Roth Capital | Buy |
| 2025-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2021-09-14 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-07-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Iniziato | Alliance Global Partners | Buy |
| 2020-07-21 | Iniziato | BMO Capital Markets | Outperform |
| 2020-07-21 | Iniziato | Barclays | Overweight |
| 2020-07-21 | Iniziato | Raymond James | Outperform |
Mostra tutto
Polypid Ltd Borsa (PYPD) Ultime notizie
Total equity of PolyPid Ltd. – FWB:2PV - TradingView
Total debt of PolyPid Ltd. – FWB:2PV - TradingView
PolyPid Ltd. Balance Sheet – FWB:2PV - TradingView
PolyPid Ltd. Stock (2PV)Quote Deutsche Boerse AG - MarketScreener
PolyPid Ltd.: Target Price Consensus and Analysts Recommendations | 2PV | IL0011326795 - MarketScreener
PolyPid Ltd.: Financial Data Forecasts Estimates and Expectations | 2PV | IL0011326795 - MarketScreener
PolyPid Ltd.: Shareholders Board Members Managers and Company Profile | IL0011326795 - MarketScreener
PolyPid Ltd.: Fundamental Analysis and Financial Ratings | 2PV | IL0011326795 - MarketScreener
Taxes of PolyPid Ltd. – FWB:2PV - TradingView
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 earnings call transcript - MSN
Net income of PolyPid Ltd. – FWB:2PV - TradingView
2PV Stock Price and Chart — FWB:2PV - TradingView
PolyPid begins rolling NDA submission for surgical infection drug By Investing.com - Investing.com South Africa
PYPD Should I Buy - Intellectia AI
Polypid Ltd Initiates D-Plex100 Nda Submission to Fda - MarketScreener
PolyPid’s Moment Is Here: NDA Submission Begins as a High-Impact Catalyst Stack Takes Shape (NASDAQ: PYPD) - TipRanks
Risk Check: Does PolyPid Ltd stock benefit from AI growth2026 Performance Recap & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Polypid initiates D-Plex100 NDA submission to the FDA - MarketScreener
PolyPid begins rolling NDA submission for surgical infection drug - Investing.com
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA - Bitget
PolyPid (PYPD) advances Fast Track NDA for D-PLEX100 after strong Phase 3 data - Stock Titan
Drug aimed at preventing surgery infections reaches FDA filing stage - Stock Titan
Aug Closing: How does PolyPid Ltd score in quality rankingsFed Meeting & Low Risk Entry Point Tips - baoquankhu1.vn
Insider Buy: Does PolyPid Ltd have high return on assetsBear Alert & Short-Term Swing Trade Alerts - baoquankhu1.vn
Patterns Watch: How much upside does PolyPid Ltd haveMarket Volume Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
PolyPid Ltd Stock: Innovative Drug Delivery Solutions in a Competitive Biotech Landscape - AD HOC NEWS
PolyPid (PYPD) COO details stock option and share holdings - Stock Titan
PolyPid (PYPD) director Dror-Darwish Nir lists six vested option grants - Stock Titan
PolyPid (PYPD) CFO details extensive employee stock option awards - Stock Titan
PolyPid (PYPD) director Barenholz discloses shares and multiple option grants - Stock Titan
PolyPid (PYPD) director Joseph BenAmram reports initial stock option grants - Stock Titan
Pullback Watch: Whats the beta of PolyPid Ltd stock2026 Risk Factors & Verified Short-Term Trading Plans - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Axsome Therapeutics (AXSM) - The Globe and Mail
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
PolyPid (PYPD) director discloses stock options on 17,456 shares - Stock Titan
PolyPid (PYPD) director details shares and vested stock options - Stock Titan
PolyPid (PYPD) CEO details stock and option holdings in Form 3 - Stock Titan
PolyPid (PYPD) deputy CEO discloses extensive employee stock options - Stock Titan
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention - TipRanks
PolyPid receives $4.3M FDA fee waiver for D-PLEX100 application By Investing.com - Investing.com India
PolyPid receives $4.3M FDA fee waiver for D-PLEX100 application - Investing.com Canada
Is PolyPid Ltd likely to announce a buybackEarnings Growth Report & Step-by-Step Trade Execution Guides - baoquankhu1.vn
PolyPid granted $4.3M waiver from FDA for D-Plex application - TipRanks
Polypid receives PDUFA fee waiver from FDA for D-Plex100's new drug application - marketscreener.com
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application - GlobeNewswire
PolyPid Ltd. (NASDAQ:PYPD) Sees Large Drop in Short Interest - MarketBeat
PolyPid Ltd Stock (ISIN: US70450B1035) Surges on Analyst Optimism: 260% Upside Forecast Signals Majo - AD HOC NEWS
Wall Street Zen Upgrades PolyPid (NASDAQ:PYPD) to Hold - MarketBeat
PolyPid at Citizens Life Sciences: Strategic Moves and Market Expansion - Investing.com India
PolyPid at Citizens Life Sciences: Strategic Moves and Market Expansion By Investing.com - Investing.com Australia
PYPD: NDA submission for D-PLEX₁₀₀ is imminent, backed by strong Phase 3 efficacy data - TradingView
Polypid Ltd Azioni (PYPD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):